Several other research firms have also commented on AIMT. Zacks Investment Research raised Aimmune Therapeutics from a sell rating to a hold rating in a research report on Monday, October 21st. ValuEngine raised Aimmune Therapeutics from a buy rating to a strong-buy rating in a research report on Monday, November 4th. Stifel Nicolaus raised Aimmune Therapeutics to a positive rating in a research report on Monday, September 16th. Goldman Sachs Group set a $27.00 target price on Aimmune Therapeutics and gave the stock a hold rating in a research report on Friday, October 25th. Finally, Royal Bank of Canada dropped their target price on Aimmune Therapeutics to $50.00 and set an outperform rating on the stock in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and an average price target of $43.11.
Aimmune Therapeutics stock traded up $1.11 during mid-day trading on Wednesday, hitting $29.48. 626,600 shares of the company were exchanged, compared to its average volume of 717,952. The business’s 50 day simple moving average is $24.90 and its two-hundred day simple moving average is $21.36. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.80 and a quick ratio of 5.80. Aimmune Therapeutics has a 12-month low of $16.95 and a 12-month high of $31.83. The company has a market capitalization of $1.82 billion, a P/E ratio of -8.03 and a beta of -0.03.
In other Aimmune Therapeutics news, CFO Eric Bjerkholt bought 1,550 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were acquired at an average cost of $22.57 per share, with a total value of $34,983.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.75% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Aperio Group LLC bought a new stake in Aimmune Therapeutics in the second quarter valued at about $76,000. Vanguard Group Inc. boosted its stake in Aimmune Therapeutics by 4.6% in the second quarter. Vanguard Group Inc. now owns 3,706,394 shares of the biotechnology company’s stock valued at $77,167,000 after acquiring an additional 164,038 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Aimmune Therapeutics by 11.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock valued at $109,234,000 after acquiring an additional 535,072 shares during the period. TD Asset Management Inc. boosted its stake in Aimmune Therapeutics by 5.7% in the second quarter. TD Asset Management Inc. now owns 100,076 shares of the biotechnology company’s stock valued at $2,084,000 after acquiring an additional 5,400 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in Aimmune Therapeutics in the second quarter valued at approximately $221,000. 78.41% of the stock is owned by hedge funds and other institutional investors.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.